Login
$SKAS
$6.50 +$0.01 (0.15%) Close

Consolidated Balance Sheets

In millions of USD; shares in millions, except per-share amounts
Q2 FY2026
As of Jun 30, 2026
Q1 FY2026
As of Mar 31, 2026
Q4 FY2025
As of Dec 31, 2025
Q3 FY2025
As of Sep 30, 2025
Q2 FY2025
As of Jun 30, 2025
Q1 FY2025
As of Mar 31, 2025
Q4 FY2024
As of Dec 31, 2024
Q3 FY2024
As of Sep 30, 2024
Q2 FY2024
As of Jun 30, 2024
Q1 FY2024
As of Mar 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q3 FY2023
As of Sep 30, 2023
Q2 FY2023
As of Jun 30, 2023
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Q3 FY2021
As of Sep 30, 2021
CURRENT ASSETS
Cash and cash equivalents
Investments
Accounts receivable
Non-Compete receivable
Inventories
Income tax receivable
Prepaid expenses
Total current assets
PROPERTY AND EQUIPMENT, net of accumulated depreciation
TOTAL ASSETS
CURRENT LIABILITIES
Accounts payable
Accrued expenses
Deferred liability
Customer deposits
Total current liabilities
Deferred liability – less current portion
TOTAL LIABILITIES
Preferred Stock, Shares Issued (in shares)
us-gaap_RetainedEarningsAccumulatedDeficit
Common stock - $0.03 par value; authorized 3,333,334; 1,010,514 shares issued and outstanding at June 30, 2026 and December 31, 2025
Additional paid-in capital
TOTAL STOCKHOLDERS’ EQUITY
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support